This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Statistics and Research Methods  • HIV/AIDS  • Neurology  • Alert me on articles by topic

David A. Ross, BMBCh, PhD; Simon Cousens, PhD; Susanne Hildegard Wedner, MSc, MD; Charalambos Sismanidis, BA(Maths),  MSc(Med Stats), PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hurwitz et al¹ present the results of a landmark placebo-controlled trial in the United States on the impact of a single daily selenium supplement on human immunodeficiency virus (HIV) disease progression (as measured by HIV viral load and CD4 cell count after 9 months). Of the participants, 73% were receiving antiretroviral therapy (ART) (76% in those allocated to selenium and 72% in those allocated to placebo). Although only 174 of 262 participants (66%) who initiated treatment were available for follow-up at 9 months and mean adherence to study treatment was estimated to have been 73% using a computerized electronic medication-monitoring cap and 81% by pill counts, follow-up rates and adherence were similar in the selenium-supplemented and placebo groups. The trial showed that at the 9-month follow-up, having been allocated to the . . . [Full Text of this Article]

AUTHOR INFORMATION